On July 10, 2024, Abbisko Therapeutics (Hong Kong Stock Exchange code: 02256) announced a positive profit alert. The company estimates its total revenue for the first half of 2024 to be approximately RMB497 million, marking a significant turnaround from deficits to profits. The profit during this period is estimated to be between RMB200 million and 220 million, representing the company's first half-yearly profit achievement.

According to the preliminary review of the company’s unaudited management accounts for the six months ended June 30, 2024, the total revenue of the company for the six months ended June 30, 2024, is expected to be approximately RMB497 million, representing an increase of RMB478 million from approximately RMB19 million for the six months ended June 30, 2023; and the company is expected to record a profit for the period within the range of RMB200 million to RMB220 million for the six months ended June 30, 2024, compared to a loss for the period of approximately RMB209 million for the six months ended June 30, 2023. Apart from the improved cost control through enhanced business operation efficiency, the anticipated increase in total revenue and turnaround from loss to profit was also mainly attributable to the out-licensing agreement for pimicotinib (ABSK021) and the upfront payment of US$70 million (RMB497 million) with MERCK, which contributed significantly to the revenue for the six months ended June 30, 2024.